Syndax CEO To Engage In The Novel Oncology Strategies At Citi Conference
Syndax CEO Michael Metzger to join a panel on novel oncology mechanisms at the Citi 2024 Global Healthcare Conference on Dec 5.


Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company focused on advancing innovative cancer therapies, has announced that its Chief Executive Officer, Michael A. Metzger, will participate in a panel discussion at the Citi 2024 Global Healthcare Conference. The panel will explore novel mechanisms in oncology and is scheduled for Thursday, December 5, 2024, at 11:00 a.m. ET. The discussion will be available for live streaming through the Investor section of Syndax’s official website, where a replay of the event will also be accessible for a limited period.

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix

Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park

Discussion